Core Insights - Vistin Pharma ASA reported strong financial results for Q4 2025, marking a record year with all-time high revenue and EBITDA [1] Financial Performance - Q4 2025 revenue reached MNOK 111, a slight decrease from MNOK 114 in Q4 2024, despite a record high sales volume increase of 9%, impacted by lower global metformin prices [2] - Full year 2025 revenue was an all-time high of MNOK 452, up from MNOK 430 in 2024, with a sales volume increase of 12% [2] - Q4 2025 EBITDA was MNOK 26, down from MNOK 28 in Q4 2024, influenced by a favorable sales volume but affected by product mix [3] - Full year 2025 EBITDA reached an all-time high of MNOK 115, a 10% increase from MNOK 104 in 2024 [3] - Earnings per share for 2025 increased to NOK 1.69 from NOK 1.42 in 2024, reflecting a 19% growth [3] Management Commentary - The CEO expressed satisfaction with the 2025 results, highlighting the company's ability to grow both top and bottom lines through effective commercial execution [4] Financial Position - The company maintains a strong balance sheet with an equity ratio of 75% and a net cash position of MNOK 16 as of year-end [4] Dividend Proposal - Based on preliminary results, the Board of Directors plans to propose an ordinary cash dividend of up to NOK 1.50 per share, to be distributed in two parts: NOK 1 in May and up to NOK 0.50 in November [5]